Celldex Therapeutics
CLDX
CLDX
149 hedge funds and large institutions have $1.7B invested in Celldex Therapeutics in 2023 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 61 increasing their positions, 44 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
7% less funds holding
Funds holding: 160 → 149 (-11)
14% less call options, than puts
Call options by funds: $4.2M | Put options by funds: $4.89M
35% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 26
Holders
149
Holding in Top 10
4
Calls
$4.2M
Puts
$4.89M
Top Buyers
| 1 | +$40.4M | |
| 2 | +$34.4M | |
| 3 | +$32.4M | |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$32.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$14.4M |
Top Sellers
| 1 | -$62.4M | |
| 2 | -$42.2M | |
| 3 | -$12.1M | |
| 4 |
Jennison Associates
New York
|
-$8.58M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.97M |